Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis B Virus Infections
Open Access
Abstract
Hepatitis B virus (HBV) infections affect approximately 296 million people around the world, and the prevalence of any past or present HBV infection during the years 2015–2018 was as high as 4.3%. Acute HBV infection often presents with nonspecific symptoms and is usually self-limited, but 5% of patients can have persistent infections leading to chronic HBV infection and the risk of turning into chronic HBV infection is significantly higher in babies with vertical transmission (95%). Patients with chronic HBV infection are usually asymptomatic, but 15 to 40% of chronic HBV carriers develop cirrhosis and/or hepatocellular carcinoma. In addition to liver-related disorders, HBV is also associated with several extrahepatic complications, including glomerulonephritis, cryoglobulinemia, neurologic disorders, psychological manifestations, polyarthritis, and dermatologic disorders. Making the diagnosis of HBV can be challenging since patients with chronic infections can remain symptom-free for decades before developing cirrhosis or hepatocellular carcinoma, and patients with acute HBV infection may have only mild, nonspecific symptoms. Therefore, understanding how this virus causes extrahepatic complications can help clinicians consider this possibility in patients with diverse symptom presentations. The pathophysiology of these extrahepatic disorders likely involves immune-related tissue injury following immune complex formation and inflammatory cascades. In some cases, direct viral infection of extrahepatic tissue may cause a clinical syndrome. Currently, the American Association for the Study of Liver Diseases recommends treatment of chronic HBV infections with interferon therapy and/or nucleos(t)ide analogs, and this treatment has been reported to improve some extrahepatic disorders in some patients with chronic HBV infection. These extrahepatic complications have a significant role in disease outcomes and increase medical costs, morbidity, and mortality. Therefore, understanding the frequency and pathogenesis of these extrahepatic complications provides important information for both specialists and nonspecialists and may help clinicians identify patients at an earlier stage of their infection.Keywords
This publication has 160 references indexed in Scilit:
- Efficacy and safety of angiotensin‐converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta‐analysis of randomized controlled trialsJournal of Cellular Biochemistry, 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infectionHepatology, 2007
- High incidence of hepatitis B virus infection in B‐cell subtype non‐Hodgkin lymphoma compared with other cancersCancer, 2007
- Short‐term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus–related polyarteritis nodosaArthritis Care & Research, 2004
- Hepatitis C virus infection in acquired aplastic anemiaAmerican Journal of Hematology, 1998
- Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infectionHepatology, 1993
- Chronic Active Hepatitis and Erythema NodosumArchives of Dermatology, 1982
- Urticaria as a Sign of Viral HepatitisArchives of Dermatology, 1972